Skip to content

13F-HR filed by Krensavage Asset Management, LLC

Krensavage Asset Management, LLC filed this 13F-HR for the quarter ended 2019-12-31, filed 2020-02-18, with 12 holding rows worth $293,048,000.

Accession
0001609251-20-000001
Filed
2020-02-18
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2019

A holdings report, 12 entries on the cover page, a total value of $293,048,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $293,048,000 with VALUE read as thousands by filing date, 13F file number 028-16807. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
UNITED THERAPEUTICS CORP DEL COM91307C102Stock460,944$40,600,000thousands by filing date
REGENERON PHARMACEUTICALS COM75886F107Stock104,420$39,208,000thousands by filing date
MCKESSON CORP COM58155Q103Stock254,330$35,179,000thousands by filing date
ALEXION PHARMACEUTICALS INC015351109COM313,556$33,911,000thousands by filing date
BIOGEN INC COM09062X103Stock109,904$32,612,000thousands by filing date
ENANTA PHARMACEUTICALS INC29251M106COM489,385$30,234,000thousands by filing date
TARO PHARMACEUTICAL INDS LTDM8737E108SHS339,819$29,880,000thousands by filing date
ALKERMES PLCG01767105SHS905,078$18,464,000thousands by filing date
RTI BIOLOGICS INC74975N105COM3,628,963$9,943,000thousands by filing date
INVACARE CORP461203101COMMON STOCK880,402$7,941,000thousands by filing date
Gilead Sciences,Inc.375558103COM121,861$7,919,000thousands by filing date
ANAPTYSBIO INC032724106COM440,409$7,157,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001609251-20-000001this filing2020-02-18acceptance time not in the bulk data set